Last reviewed · How we verify
Fresh frozen plasma
Fresh frozen plasma replaces deficient clotting factors and other plasma proteins to restore hemostatic function in patients with coagulopathy or massive bleeding.
Fresh frozen plasma replaces deficient clotting factors and other plasma proteins to restore hemostatic function in patients with coagulopathy or massive bleeding. Used for Coagulopathy with active bleeding or high bleeding risk, Massive transfusion / dilutional coagulopathy, Multiple clotting factor deficiency.
At a glance
| Generic name | Fresh frozen plasma |
|---|---|
| Also known as | FFP, Blood Transfusion Centre Fresh Frozen Plasma, FFP, plasma, Blood products |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Blood product / Plasma derivative |
| Modality | Biologic |
| Therapeutic area | Hematology / Transfusion Medicine |
| Phase | FDA-approved |
Mechanism of action
Fresh frozen plasma (FFP) is a blood product containing all vitamin K-dependent clotting factors (II, V, VII, X), fibrinogen, and other plasma proteins. It is used to correct multiple factor deficiencies when specific factor replacement is unavailable or impractical, or in massive transfusion protocols to restore coagulation capacity and prevent dilutional coagulopathy.
Approved indications
- Coagulopathy with active bleeding or high bleeding risk
- Massive transfusion / dilutional coagulopathy
- Multiple clotting factor deficiency
- Reversal of warfarin in emergency settings (when prothrombin complex concentrate unavailable)
- Thrombotic thrombocytopenic purpura (TTP) plasma exchange
Common side effects
- Volume overload / fluid overload
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Transfusion-transmitted infection (rare with modern screening)
- Citrate toxicity (hypocalcemia)
Key clinical trials
- Plasma Relaxin Measurement Based on Endometrial Preparation for Embryo Transfer
- Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) (PHASE3)
- Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study (NA)
- Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery (PHASE2)
- Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura (NA)
- FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial (PHASE2, PHASE3)
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCa
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fresh frozen plasma CI brief — competitive landscape report
- Fresh frozen plasma updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI